BOLT

Bolt Biotherapeutics Inc

6.59

Oct 30 • 3:59 PM ET +0.23 (3.62%)

6.42

Aftermarket • 5:58 PM ET -0.17 (-2.58%)

Healthcare Biotechnology USA Nano NASD

Peers: STRO HOWL PYXS CTMX XLO CRBP ZYME STTK ALXO CUE

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	12.69M
Enterprise Value	16.51M
Income	-28.74M
Sales	4.70M
Book/sh	6.56
Cash/sh	9.24
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	23
IPO	Feb 05, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	2.70
P/B	1.00
P/C	0.71
P/FCF	-
EV/EBITDA	-
EV/Sales	3.51
Quick Ratio	2.61
Current Ratio	2.61
Debt/Eq	1.71
LT Debt/Eq	1.47
Option/Short	No / Yes

EPS (ttm)	-16.44
EPS next Y	-20.19
EPS next Q	-3.69
EPS this Y	-2.35%
EPS next Y	-10.51%
EPS next 5Y	-19.99%
EPS past 3/5Y	27.67% 11.84%
Sales past 3/5Y	10.33% 101.61%
EPS Y/Y TTM	37.93%
Sales Y/Y TTM	12.79%
EPS Q/Q	-2.29%
Sales Q/Q	-99.72%
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-34.94% -99.00%

Insider Own	14.93%
Insider Trans	-11.52%
Inst Own	18.17%
Inst Trans	-2.31%
ROA	-49.62%
ROE	-111.65%
ROIC	-92.19%
Gross Margin	80.45%
Oper. Margin	-605.85%
Profit Margin	-611.47%
SMA20	39.39%
SMA50	59.32%
SMA200	46.20%
Trades

Shs Outstand	1.93M
Shs Float	1.64M
Short Float	0.96%
Short Ratio	0.07
Short Interest	0.02M
52W High	7.78 -15.30%
52W Low	3.10 112.58%
Volatility	7.14% 9.84%
ATR (14)	0.54
RSI (14)	75.17
Beta	0.99
Rel Volume	1.06
Avg Volume	236.85K
Volume	249,919

Perf Week	5.10%
Perf Month	87.75%
Perf Quarter	65.58%
Perf Half Y	30.24%
Perf YTD	20.52%
Perf Year	15.00%
Perf 3Y	-66.72%
Perf 5Y	-97.48%
Perf 10Y	-
Recom	1.67
Target Price	48.50
Prev Close	6.36
Price	6.59
Change %	3.62%

Consensus

Buy

Avg. Price Target

$48.50

Implied Upside

+636.0%

Analysts6incl. previous ratings

Rating Distribution5 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 29, 2026	Initiated	RRodman & Renshaw	Buy	$22	+233.8%
Oct 20, 2025	Resumed	HH.C. Wainwright	Buy	$7	+6.2%
Jan 06, 2022	Downgrade	MMorgan Stanley	Overweight → Equal-Weight
Mar 02, 2021	Initiated	SSVB Leerink	Outperform	$36	+446.3%
Mar 02, 2021	Initiated	SStifel	Buy	$40	+507.0%
Mar 02, 2021	Initiated	MMorgan Stanley	Overweight	$45	+582.9%
Mar 02, 2021	Initiated	GGuggenheim	Buy	$42	+537.3%

Oct-28-26 09:27AM	Lilly shuffles business structure; Novartis writes off part of Avidity deal (BioPharma Dive)
Oct-23-26 09:08AM	Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications (GlobeNewswire) +49.64%
Aug-11-26 04:41PM	Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot (Associated Press) -13.32%
04:05PM	Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-12-26 04:18PM	Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-26 04:51PM	Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-24-26 08:00AM	Bolt Biotherapeutics to Participate in Upcoming March Conferences (GlobeNewswire)
Nov-12-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:21PM	Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 10:00AM	Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -9.68%
Oct-01-25 04:05PM	Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 (GlobeNewswire) +6.39% -12.37%
Aug-14-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -5.33%
04:24PM	Loading…
04:24PM	Bolt Biotherapeutics Inc.: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-25 08:00AM	ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-07-25 08:10AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
May-12-25 05:25PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.70%
05:10PM	Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:28PM	Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-08-25 05:50PM	Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates (GlobeNewswire)
Apr-30-25 04:05PM	Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 (GlobeNewswire)
Apr-25-25 01:00PM	Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 (GlobeNewswire)
Mar-25-25 04:30PM	Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 (GlobeNewswire)
Mar-24-25 04:37PM	Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot (Associated Press Finance)
04:20PM	Loading…
04:20PM	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 04:05PM	Bolt Biotherapeutics to Participate in Upcoming March Conferences (GlobeNewswire)
Feb-11-25 04:05PM	Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. (GlobeNewswire)
Nov-12-24 05:35PM	Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-24 10:00AM	Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting (GlobeNewswire)
Sep-04-24 04:05PM	Bolt Biotherapeutics Announces Changes to its Board of Directors (GlobeNewswire)
Aug-28-24 07:00AM	Bolt Biotherapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-13-24 04:05PM	Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-24-24 06:13AM	The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows (InvestorPlace)
May-15-24 03:00PM	Bolt Biotherapeutics Inc (BOLT) (Q1 2024) Earnings Call Transcript Highlights: Strategic Shifts ... (GuruFocus.com) -37.12%
01:34PM	Top Midday Decliners (MT Newswires)
08:05AM	Bolt Biotherapeutics to lay off staff, abandon lead ADC candidate (BioPharma Dive)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-14-24 10:54PM	BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team (GlobeNewswire)
Mar-21-24 10:53PM	BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-24 07:00AM	Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Dec-21-23 07:30AM	Pacira Appoints Frank D. Lee as Chief Executive Officer (GlobeNewswire)
Dec-05-23 07:00AM	Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu (GlobeNewswire)
Nov-09-23 04:05PM	Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-23 07:00AM	Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-23-23 10:30AM	Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress (GlobeNewswire) -7.80%
Oct-18-23 07:00AM	Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual Meeting (GlobeNewswire)
Oct-17-23 07:00AM	Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers (GlobeNewswire)
Oct-16-23 07:00AM	Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023 (GlobeNewswire) +6.25%
Sep-28-23 07:00AM	Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers (GlobeNewswire)
Sep-12-23 08:05AM	Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042 (GlobeNewswire)
Sep-05-23 04:15PM	Bolt Biotherapeutics to Participate in September Investor Conferences (GlobeNewswire)
Aug-09-23 06:10AM	Bolt Biotherapeutics Second Quarter 2023 Earnings: Misses Expectations (Simply Wall St.)
Aug-07-23 04:10PM	Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-23 07:30AM	Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer (GlobeNewswire)
Jul-31-23 05:27PM	Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jun-13-23 11:22AM	Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-30-23 08:00AM	BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases (PR Newswire) -6.56%
May-25-23 05:05PM	Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting (GlobeNewswire)
May-11-23 04:05PM	Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +12.50%
Apr-26-23 10:00AM	Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-11-23 07:41AM	Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last year (Simply Wall St.)
Mar-30-23 01:16PM	Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies (Benzinga)
Mar-29-23 04:15PM	Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
04:05PM	Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies (GlobeNewswire)
Mar-14-23 04:30PM	Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting (GlobeNewswire) +7.86%
Feb-28-23 08:00AM	Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-01-23 08:00AM	Bolt Biotherapeutics to Present at February Investor Conferences (GlobeNewswire)
Jan-04-23 09:31AM	Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation (Simply Wall St.)
Dec-14-22 04:43PM	Bolt Biotherapeutics Appoints Laura Berner to Board of Directors (GlobeNewswire)
Nov-10-22 04:05PM	Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 08:00AM	Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting (GlobeNewswire)
Nov-02-22 07:20AM	Investors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last year (Simply Wall St.)
Nov-01-22 10:01AM	Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:00AM	Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference (GlobeNewswire)
Sep-09-22 12:08PM	16 Best Penny Stocks to Buy Now (Insider Monkey)
Aug-31-22 07:30AM	Bolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference (GlobeNewswire)
Aug-25-22 12:23PM	Eli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead? (Zacks)
12:02PM	J&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvayli (Zacks)
Aug-10-22 04:05PM	Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +10.53% -6.35%
Jul-22-22 08:44AM	Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) -5.75%
Jun-10-22 07:21AM	Zacks.com featured highlights include Carriage Services, Pool, The Buckle, Bolt Biotherapeutics and Titan Machinery (Zacks) -6.57%
May-27-22 08:00AM	Bolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022 (GlobeNewswire)
May-26-22 06:52AM	The past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitable (Simply Wall St.)
May-13-22 08:28AM	The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma (Zacks)
May-12-22 04:05PM	Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +5.41%
May-11-22 07:32AM	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates (Zacks) -10.30%
Apr-07-22 08:00AM	Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference (GlobeNewswire)
Mar-30-22 04:05PM	Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-08-22 04:30PM	Bolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022 (GlobeNewswire) +15.20%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yonehiro Grant	Chief Operating Officer	Sep 18 '26	Sale	3.24	6,850	22,169	17,269	Sep 21 06:05 PM
Yonehiro Grant	Chief Operating Officer	Sep 17 '26	Sale	3.32	4,909	16,290	24,119	Sep 21 06:05 PM
Yonehiro Grant	Chief Operating Officer	Sep 16 '26	Sale	3.77	1,417	5,348	29,028	Sep 21 06:05 PM
Nemec Sarah	Senior VP, Finance and PAO	Jun 05 '26	Buy	3.88	509	1,973	1,924	Sep 21 06:04 PM
Nemec Sarah	Senior VP, Finance and PAO	Sep 18 '26	Sale	3.24	4,077	13,195	17,082	Sep 21 06:04 PM
Nemec Sarah	Senior VP, Finance and PAO	Sep 17 '26	Sale	3.32	2,922	9,696	21,159	Sep 21 06:04 PM
Nemec Sarah	Senior VP, Finance and PAO	Sep 16 '26	Sale	3.77	843	3,181	24,081	Sep 21 06:04 PM
Quinn William P.	President, CEO and CFO	Jun 05 '26	Buy	3.88	637	2,469	2,950	Sep 21 06:03 PM
Quinn William P.	President, CEO and CFO	Sep 18 '26	Sale	3.24	9,132	29,555	25,384	Sep 21 06:03 PM
Quinn William P.	President, CEO and CFO	Sep 17 '26	Sale	3.32	6,545	21,718	34,516	Sep 21 06:03 PM
Quinn William P.	President, CEO and CFO	Sep 16 '26	Sale	3.77	1,889	7,129	41,061	Sep 21 06:03 PM
Quinn William P.	President, CEO and CFO	Dec 05 '25	Buy	4.61	125	576	2,313	Feb 04 04:32 PM
Nemec Sarah	Senior VP, Finance and PAO	Dec 05 '25	Buy	4.61	125	576	1,415	Feb 04 04:32 PM

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

CEOMr. William P. Quinn

M.B.A.Mr. Grant Yonehiro C.F.A.

Senior VP of Finance & Principal Accounting OfficerMs. Sarah Nemec

Senior Vice President of ResearchDr. Michael N. Alonso Ph.D.

Senior Principal ScientistMr. Justin Kenkel

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BOLT

Bolt Biotherapeutics Inc

Upgrade your Finviz experience